Tiziana Life Sciences opened higher at $0.63, compared with its previous close of $0.62. In the last trading session, the stock traded between $0.61 and $0.65. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Tiziana Life Sciences is now worth
$ 44.78
Resulting in a loss of
$ 55.22 (55.22%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.00 (-0.48%)
Day High
$0.65
Day Low
$0.61
Day Open
$0.63
Prev Close
$0.62
Volume
1,90,511
1W Return
-2.98%
1M Return
-42.78%
3M Return
-38.51%
6M Return
-59.61%
1Y Return
-64.48%
Market Cap ($ Mn)
73
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-411.98%
EPS (TTM)
-
1 Week
-2.98%
1 Month
-42.78%
3 Months
-38.51%
6 Months
-59.61%
9 Months
-55.54%
No data available.
Tiziana links INFORM-MS data to EA program, confirms safety profile
Phase 2a INFORM-MS trial confirms EA program trends in na-SPMS patients. 50 μg dose showed significant microglial activation reduction (p=0.0168). Both dose arms improved MFIS fatigue scores beyond clinical relevance thresholds. No anti-drug antibodies detected in EA program over 37.4 patient-years.
3 days agoTiziana Life Sciences completes dosing in Alzheimer's Phase 2 trial
Last patient dosed in Phase 2 trial for early/mild Alzheimer's disease. Topline data expected in Q1 2027. Trial tests intranasal foralumab as monotherapy and combo with lecanemab/donanemab. Prior na-SPMS Expanded Access Program showed stability or improvement in all 14 patients.
27 days agoTiziana Life Sciences doses first participants in ALS BANYAN trial
First three participants dosed with intranasal foralumab in Phase 2a BANYAN trial. Study evaluates safety and biological effects in early-stage ALS patients. Trial sponsored by Tiziana and co-funded by the ALS Association. Dosing initiated at Healey & AMG Center in Boston, Massachusetts.
1mo agoTiziana Life Sciences completes Phase 2a MS trial, data due October
Last patient completed last visit in Phase 2a INFORM-MS trial for na-SPMS. Database lock expected this week with topline data release in October. Trial enrolled 48 patients across three cohorts at U.S. sites. Expanded access data shows stabilization or improvement in most patients.
1mo agoTiziana Life Sciences to present Phase 2a ALS trial poster at Nexus 2026
Tiziana Life Sciences to present Phase 2a BANYAN trial poster at ALS Nexus 2026. Intranasal foralumab targets regulatory T cells to modulate neuroinflammation in ALS. Trial uses 3:1 randomization ratio and leverages Healey ALS MyMatch infrastructure. Expanded access program shows disease stability or improvement in 14 MS patients.
2mo agoTiziana Life Sciences sees 34% brain inflammation drop in MSA trial
Tiziana Life Sciences reported that the third MSA patient in its Phase 2 trial showed up to 34% SUV and 26% SUVR reduction in brain inflammation after treatment with intranasal foralumab. These results align with prior patients, demonstrating consistent biological activity in reducing neuroinflammation. The company is advancing foralumab, a fully human anti-CD3 monoclonal antibody, across multiple neurodegenerative indications including MS and Alzheimer's.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Tiziana Life Sciences is now worth
$ 44.78
Resulting in a loss of
$ 55.22 (55.22%)
Note: Past profits do not guarantee future returns.
